Genomic Expression Nominated to Compete in Always On's Venture Summit Mid-Atlantic Top 100

Online, September 12, 2011 (Newswire.com) - Genomic Expression, Inc. has been nominated for Always On's top 100 list. To qualify for inclusion in the list of the top emerging companies, Genomic Expression had to demonstrate significant market traction, pursuit of game-changing technology and the ability to create new business opportunities in high-growth markets.

"We are excited to receive this nomination, and are looking forward to the competition and presenting at IMPACT" says Gitte Pedersen, CEO Genomic Expression.

The winners of this competition will be officially announced in mid November and will be honored at IMPACT 2011 Venture Summit Mid-Atlantic, November 29-30, 2011, at the Ritz Carlton Hotel, the Pennsylvania Convention Center, and the Crystal Tea Room, in Philadelphia, PA, and will be featured in the Venture Summit Mid-Atlantic program guide and on the Always On website.

About Genomic Expression

Genomic Expression is developing proprietary cost-effective genomics diagnostics tools for personalized medicine, making research and delivery of healthcare more effective.

Genomic Expressions sequencing platform reduces the amount of data processing without losing information. Due to these features, the data doesn't have to be re-engineered to other platforms for diagnostic applications.

The technology is based on an intelligent target filtering technology integrated with sequencing short reads on a small chip. The technology allows the integration of sample preparation, detection, and analyses into one device addressing the main bottlenecks in the current sequencing platforms.

In addition, Genomic Expression is developing genomic signatures that translate into information on treatment options that is easy for doctors to understand, supported by a $30 million grant project.

"Our vision is that personalized medicine can create a better and more efficient healthcare system. We will become the diagnostic platform of choice due to our technology's flexibility, robustness, and attractive price point", says Gitte Pedersen, CEO.

As a part of the $30 million grant project, Genomic Expression has access to laboratory space, equipment, top researchers, the largest bioinformatics institute in Europe, and 15 million biological samples linked to cradle-to-grave electronic medical records, making the company very capital efficient.